Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Transcenta Holding Limited ( (HK:6628) ) is now available.
Transcenta Holding Limited announced that its partner, Inhibrx Biosciences, has reported positive Phase 2 results for ozekibart in treating chondrosarcoma, a cancer with no approved systemic options. The promising results from the ChonDRAgon study highlight ozekibart’s potential as a significant treatment option, with plans for a Biologics License Application submission by 2026. This development strengthens Transcenta’s position in the oncology sector, particularly in regions where it holds exclusive commercialization rights.
The most recent analyst rating on (HK:6628) stock is a Sell with a HK$3.00 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.
More about Transcenta Holding Limited
Transcenta Holding Limited is a biotechnology company focused on developing and commercializing innovative therapies, primarily in the field of oncology. The company holds exclusive rights to develop and commercialize certain therapies in mainland China, Hong Kong SAR, Macau SAR, and Taiwan.
Average Trading Volume: 3,977,529
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.36B
See more data about 6628 stock on TipRanks’ Stock Analysis page.